A Phase 3 trial that Roche and Ionis have been running in IgA nephropathy just cleared its most important early hurdle: the IMAgINATION study met its prespecified interim primary endpoint, showing a statistically significant and clinically meaningful reduction in proteinuria in adults with primary IgAN. That result, from an ongoing trial rather than a completed one, gives both companies their first hard evidence that sefaxersen works in a randomized Phase 3 setting.
The drug’s mechanism is direct. Sefaxersen is an antisense oligonucleotide that suppresses complement factor B production in the liver, cutting off the alternative complement pathway that drives kidney damage in IgAN. Proteinuria, the primary endpoint here, reflects how much protein leaks through damaged kidney filters into urine, and a reduction in it is accepted as a meaningful indicator of slowing disease progression. The interim data suggest the mechanism is translating into measurable kidney protection.
Roche licensed sefaxersen from Ionis in stages: a $75 million option payment in 2018, then a $55 million upfront license in 2022 specifically for IgAN. Ionis also stands to collect milestone payments and royalties, so a successful interim readout carries financial weight for both sides. The partnership has now produced data strong enough to sustain the full trial.
Because this is a prespecified interim analysis rather than a final readout, the trial continues, and regulators will ultimately review the full dataset. The number to track from here is whether the proteinuria reduction holds at the trial’s primary completion, since interim efficacy in kidney disease trials has not always survived to final analysis in this indication. The strength of that effect size, when Roche and Ionis disclose it, will determine whether regulators see a clear enough benefit to act.
Source link: https://www.sec.gov/Archives/edgar/data/874015/000114036126037371/ef20082626_8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
